Alivus Life Sciences Limited
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib… Read more
Market Cap & Net Worth: Alivus Life Sciences Limited (ALIVUS)
Alivus Life Sciences Limited (NSE:ALIVUS) has a market capitalization of $1.33 Billion (₹114.89 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #12339 globally and #526 in its home market, demonstrating a 1.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alivus Life Sciences Limited's stock price ₹936.10 by its total outstanding shares 122736348 (122.74 Million).
Alivus Life Sciences Limited Market Cap History: 2025 to 2026
Alivus Life Sciences Limited's market capitalization history from 2025 to 2026. Data shows growth from $1.30 Billion to $1.33 Billion (0.00% CAGR).
Alivus Life Sciences Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alivus Life Sciences Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Alivus Life Sciences Limited's market cap is 0.05 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.27x
Alivus Life Sciences Limited's market cap is 0.27 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $1.30 Billion | $23.72 Billion | $4.86 Billion | 0.05x | 0.27x |
Competitor Companies of ALIVUS by Market Capitalization
Companies near Alivus Life Sciences Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Alivus Life Sciences Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Alivus Life Sciences Limited Historical Marketcap From 2025 to 2026
Between 2025 and today, Alivus Life Sciences Limited's market cap moved from $1.30 Billion to $ 1.33 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹1.33 Billion | +2.13% |
| 2025 | ₹1.30 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Alivus Life Sciences Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.33 Billion USD |
| MoneyControl | $1.33 Billion USD |
| MarketWatch | $1.33 Billion USD |
| marketcap.company | $1.33 Billion USD |
| Reuters | $1.33 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.